ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,617.87
-0.42%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) Noticias

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ACRV
FechaHoraFuenteTítuloSímboloCompañía
18/11/202415:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202406:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202406:00GlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
17/10/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
16/10/202415:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202407:00GlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
14/09/202402:10GlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
10/09/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
09/09/202406:00GlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202407:00GlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
29/05/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
16/05/202417:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
14/05/202407:00GlobeNewswire Inc.Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
24/04/202415:01GlobeNewswire Inc.Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventNASDAQ:ACRVAcrivon Therapeutics Inc
16/04/202419:01GlobeNewswire Inc.Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
10/04/202407:00GlobeNewswire Inc.Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable ResistancNASDAQ:ACRVAcrivon Therapeutics Inc
09/04/202406:00GlobeNewswire Inc.Acrivon Therapeutics Announces $130 Million Private Placement FinancingNASDAQ:ACRVAcrivon Therapeutics Inc
28/03/202407:00GlobeNewswire Inc.Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
05/03/202415:30GlobeNewswire Inc.Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
04/03/202407:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
27/02/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
13/02/202414:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRVAcrivon Therapeutics Inc
08/02/202407:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
06/02/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
12/01/202415:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
04/01/202407:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
17/12/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRVAcrivon Therapeutics Inc
01/12/202315:35Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRVAcrivon Therapeutics Inc
28/11/202307:58Dow Jones NewsAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer AssayNASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Su Consulta Reciente

NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
COIN
XRPUSD
Ripple
SPI
SP500
S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
BAC
Bank of America
COIN
AVAXUSD
Avalanche
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
NYSE
AXP
American Express
AMEX
XLE
Energy Select Sector SPDR
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados